291 related articles for article (PubMed ID: 35090580)
1. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
Kaplonek P; Fischinger S; Cizmeci D; Bartsch YC; Kang J; Burke JS; Shin SA; Dayal D; Martin P; Mann C; Amanat F; Julg B; Nilles EJ; Musk ER; Menon AS; Krammer F; Saphire EO; Andrea Carfi ; Alter G
Immunity; 2022 Feb; 55(2):355-365.e4. PubMed ID: 35090580
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Richardson SI; Manamela NP; Motsoeneng BM; Kaldine H; Ayres F; Makhado Z; Mennen M; Skelem S; Williams N; Sullivan NJ; Misasi J; Gray GG; Bekker LG; Ueckermann V; Rossouw TM; Boswell MT; Ntusi NAB; Burgers WA; Moore PL
Cell Rep Med; 2022 Feb; 3(2):100510. PubMed ID: 35233544
[TBL] [Abstract][Full Text] [Related]
4. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
[TBL] [Abstract][Full Text] [Related]
5. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.
Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J
Front Immunol; 2024; 15():1392477. PubMed ID: 38774878
[TBL] [Abstract][Full Text] [Related]
6. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
[TBL] [Abstract][Full Text] [Related]
7. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
8. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
9. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.
Cho A; Muecksch F; Schaefer-Babajew D; Wang Z; Finkin S; Gaebler C; Ramos V; Cipolla M; Mendoza P; Agudelo M; Bednarski E; DaSilva J; Shimeliovich I; Dizon J; Daga M; Millard KG; Turroja M; Schmidt F; Zhang F; Tanfous TB; Jankovic M; Oliveria TY; Gazumyan A; Caskey M; Bieniasz PD; Hatziioannou T; Nussenzweig MC
Nature; 2021 Dec; 600(7889):517-522. PubMed ID: 34619745
[TBL] [Abstract][Full Text] [Related]
11. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
[TBL] [Abstract][Full Text] [Related]
12. Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
Du PX; Chang SS; Ho TS; Shih HC; Tsai PS; Syu GD
Virulence; 2024 Dec; 15(1):2351266. PubMed ID: 38717195
[No Abstract] [Full Text] [Related]
13. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
15. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.
Kaplonek P; Cizmeci D; Fischinger S; Collier AR; Suscovich T; Linde C; Broge T; Mann C; Amanat F; Dayal D; Rhee J; de St Aubin M; Nilles EJ; Musk ER; Menon AS; Saphire EO; Krammer F; Lauffenburger DA; Barouch DH; Alter G
Sci Transl Med; 2022 May; 14(645):eabm2311. PubMed ID: 35348368
[TBL] [Abstract][Full Text] [Related]
16. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Lucas C; Vogels CBF; Yildirim I; Rothman JE; Lu P; Monteiro V; Gehlhausen JR; Campbell M; Silva J; Tabachnikova A; Peña-Hernandez MA; Muenker MC; Breban MI; Fauver JR; Mohanty S; Huang J; ; Shaw AC; Ko AI; Omer SB; Grubaugh ND; Iwasaki A
Nature; 2021 Dec; 600(7889):523-529. PubMed ID: 34634791
[TBL] [Abstract][Full Text] [Related]
17. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
[No Abstract] [Full Text] [Related]
18. Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.
Klingler J; Kowdle S; Bandres JC; Emami-Gorizi R; Alvarez RA; Rao PG; Amanat F; Gleason C; Kleiner G; Simon V; Edelstein A; Perandones C; Upadhyay C; Lee B; Hioe CE
Front Immunol; 2024; 15():1382619. PubMed ID: 38779671
[TBL] [Abstract][Full Text] [Related]
19. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
20. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
Kaku CI; Champney ER; Normark J; Garcia M; Johnson CE; Ahlm C; Christ W; Sakharkar M; Ackerman ME; Klingström J; Forsell MNE; Walker LM
Science; 2022 Mar; 375(6584):1041-1047. PubMed ID: 35143256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
